Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10

Today

02:16
Alligator Bioscience today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company's lead asset, mitazalimab. All patients in the 450 µg/kg cohort have been dosed and there have been no adverse effects related to...

01:51
InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first patient in China has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two...

01:13
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of  "Uncovering the high prevalence of bacterial burden in surgical site wounds with...

00:05
Ionis Pharmaceuticals, Inc. announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in Huntington's disease (HD). After halting dosing in the Phase 3 GENERATION HD1 study, exploratory post-hoc analyses suggest...

00:01
Hyivy Health, an innovative FemTech startup developing a first-of-its-kind pelvic health rehabilitation system has raised $1.1 million in pre-seed funding. The innovative pelvic health technology includes a multi-therapy...


17 january 2022

19:00
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing in its Phase 2b clinical trial of XW003...

12:29
PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotech company focused on the research, development and manufacturing of "psychedelic" pharmaceuticals in the MDXX class, is pleased to announce that the Company's has initiated...

09:00
Akseera Pharma Corp., a Canadian company, is leading the research surrounding CBD and COVID-19. Specifically, they have collaborated with premier universities studying the potential of CBD as a therapeutic. Akseera has been scientifically...

07:30
With a mission of "Bolstering human immunity by utilizing empowered antibody therapies", the SparX Group is rapidly becoming a significant player in the field of discovering unique therapeutic target combinations and development of novel bispecific...

06:06
Digbi Health today announced incorporating ethnic-specific risk scores for nutrition, fitness, obesity, diabetes, hypertension, mental and digestive health across its virtual care program for people living with polychronic physical and  mental...

05:04
ZURICH, Jan. 17, 2022  Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in...

04:53
Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a first-in-class, subcutaneously...

03:48
The Philippines has approved Recombinant Two-Component COVID-19 Vaccine (ReCOV) developed by...

01:29
On January 13, 2022, Green Valley (Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of...


16 january 2022

20:04
Jacobio's self-developed global first-in-class drug Aurora A inhibitor  JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in patients with...


14 january 2022

12:01
As COVID-19 infections continue to soar across Minnesota and in the Twin Cities, GS Labs has experienced a sustained surge in Minnesotans seeking rapid tests to determine their current infection status....

12:00
Medtronic plc , a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center study1 showing meaningful pain relief using DTMtm SCS endurance therapy, a modified, lower-energy variation of...

08:07
Cantargia AB today reported treatment of the first triple negative breast cancer (TNBC) patient with nadunolimab and chemotherapy in the phase Ib/II clinical trial TRIFOUR. This trial, performed in collaboration with the Spanish Breast Cancer Group,...

08:00
Numinus Wellness Inc. ("Numinus") , a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its Phase 1 study, HOPE, on a naturally derived...

07:00
Universal Ibogaine Inc. ("UI" or the "Company") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to introduce its contract research organization ("CRO") partners who will enable...

06:18
LumiraDx , a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant.  In-house wet testing with live...


13 january 2022

10:35
- In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the median time to viral RNA clearance by at least 4 days; Median of 10 days for viral clearance in the opaganib arm vs. clearance median...

09:50
Patients hospitalized for COVID-19 had higher levels over the short term of blood proteins known to rise with neurological damage than non-COVID-19 patients diagnosed with Alzheimer's disease, a new study finds....

09:01
ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of Augmented ePRO, a first-of-its-kind offer in tech-enabled clinical trial service that combines AI-assisted ePRO instruments with a centralized clinical rating...

09:00
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to study...

08:35
Vios Fertility Institute (Vios) - a global leader in fertility treatment, research and science - expands their network partnership with TMRW Life Sciences (TMRW) to implement a state-of-the-art cryo management solution for fertility specimens at...

08:00
SynerFuse, Inc., a Minneapolis-based medical device company, is pleased to announce the first implantation in the company's proof-of-concept study. The study will evaluate the safety and tolerability of simultaneously implanting spinal fusion...

08:00
Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Accuredit), an emerging company based on new generations of safe and highly targeted gene editing therapies, and N1 Life, a biotech company focused on developing cutting-edge drug...

08:00
RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, today announced a significant growth investment from LLR Partners. The capital and resources from this partnership will be dedicated to...

08:00
On Target Laboratories, Inc., a privately-held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery, today announced the completion of the Phase 3, randomized, multi-center, single...

07:57
Medical device company, Neuromod Devices Ltd, has launched Ótologie, a specialist telehealth service for tinnitus. This new service will provide tinnitus patients, throughout the United Kingdom and Europe, with a...

04:30
Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates...

04:16
BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership. The three-year expansion includes...

02:28
Oncopeptides AB (publ) , a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the data from the randomized head-to-head phase 3 OCEAN study, evaluating the efficacy and...


12 january 2022

11:00
Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion and positive results of ALA-1000 SAD study...

09:49
Alar Pharmaceuticals Inc. (Alar, TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces the completion and positive results of ALA-1000 SAD study...

09:30
RegeneRx Biopharmaceuticals, Inc.  ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published an update regarding the regulatory progress of RGN-259 on the Company's...

09:00
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic...

08:59
CRIO, a Boston-based technology firm streamlining clinical trials for sponsors, sites and patients, announced it has closed a $9M in Series B financing. The round was led by Abbhi Capital with participation from Rally Ventures and NXT Ventures, lead...

08:45
Oramed Pharmaceuticals Inc. , a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. To see a video message from the...

08:42
Pacific Neuroscience Institute (PNI) located at Providence Saint John's Health Center, has activated a new psilocybin clinical trial and has begun participant enrollment. The PSIL201 study is investigating the safety and efficacy of psilocybin for...

08:30
AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of an editorial regarding the use of...

08:00
I-Mab (the "Company") , a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient had been dosed in its China phase 2 study (NCT05145907) of...

08:00
Biotechnology company Evolved by Nature announced today that sister company Silk Medical Aesthetics has received Investigational Device Exemption (IDE) approval from the FDA to initiate a pivotal clinical trial for its new dermal filler for the...

08:00
?OncoHost,?a global leader in?next-generation precision oncology?for improved personalized cancer therapy, today announced results from its ongoing multicenter clinical trial, PROPHETIC. These interim results confirm that through proteomic analysis...

06:03
Lantern Pharma , a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has expanded...

06:00
Bionomics Limited (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022. Dr Errol De Souza, Executive Chairman of Bionomics,...

06:00
Stratustm Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced three new patents today. The patents, which issued in the United States, Brazil, and India, demonstrate continued growth of the...

06:00
Hallux Inc., a clinical stage pharmaceutical company, today announced that patient screening has begun for a phase 2 clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of Hallux Subungual Gel (HSG) in patients with...

05:00
POSITIVE IMPACTS INCLUDE REDUCED VIRAL LOAD AND HIGHER REMISSION RATES PASADENA, Texas, Jan. 12, 2022 /CNW/ -- A newly published...

1 2 3 4 5 6 7 8 9 10